As of 14 Oct 2026, Diagonal Therapeutics has raised $125M across 1 verified round on record; latest: $125 million Series B led by Janus Henderson Investors and Sanofi Ventures, announced 8 Jan 2026.
They develop innovative clustering antibodies for the treatment of genetic diseases.
diagonaltx.comBiotech
1 source
Watertown, Mass. appears as the dateline, not as a stated headquarters.
Published by hand (vcaonline.com): "Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, today announced the closing of an oversubscribed $125 million Series B financing.": biggest-rounds completeness (K): the round's own page (company, lead investor or trade press) states it
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2026-01-08 | Janus Henderson Investors, Sanofi Ventures | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source Watertown, Mass. appears as the dateline, not as a stated headquarters. Published by hand (vcaonline.com): "Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, today announced the closing of an oversubscribed $125 million Series B financing.": biggest-rounds completeness (K): the round's own page (company, lead investor or trade press) states it [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: vcaonline.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage | ||||